https://www.live-feeds.com/feed/moderna-mrna-vaccine-almost-halves-the-risk-of-skin-cancer-returningContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-mrna-vaccine-almost-halves-the-risk-of-skin-cancer-returninghttps://www.live-feeds.com/feed/moderna-mrna-vaccine-almost-halves-the-risk-of-skin-cancer-returning#u164350Fri, 30 Oct 2026 15:36:02 +0000A personalized mRNA cancer vaccine developed by Moderna and Merck cuts the risk of death or melanoma recurrence by 42 percent in late-stage trial results. The long-awaited data for treatment-resistant melanoma prompted an early release after a data leak ahead of an official presentation. While oncologists praised the positive findings as a major advancement, Moderna shares plunged following the leak as investors digested the trial details. More research is required to speed up personalized therapies and target other tumors.Why it mattersThe late-stage trial evaluation centers on treatment-resi